A company based on Nobel Prize-winning research is changing the way genetic disorders are treated. It has already approved its first CRISPR therapy and its further development promises major transformational potential.

CRISPR/Cas9 technology has opened a new chapter in medicine - and this company is on the verge of putting it into practice. It emerged directly from the lab of Emmanuelle Charpentier, who won a Nobel Prize for her discovery of gene editing. Today, it has an approved treatment for sickle cell anaemia and, in partnership with Vertex Pharmaceuticals, is expanding its scope to include oncology, autoimmune disorders and diabetes. With a robust financial background and an advanced clinical pipeline, this stock is a strong candidate for a long-term growth story.

✅ Top analysis points

• First approved CRISPR gene therapy
• Partnership with a major pharmaceutical player and shared revenue from commercialization
• Strong capital position: Cash on hand of over $1.8 billion, no debt
• Advanced pi…